NASDAQ · Financial Statements
Neoleukin Therapeutics, Inc. (NLTX) Financial Statements
$3.49
NASDAQ: NLTX
Market Cap $8.20M
Overview Financials Dividend
Neoleukin Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $90.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2024 2025
Revenue $0 $0 $0 $0 $0 Operating Profit $-34.0M $-61.0M $-59.0M $-83.0M $-103.0M Net Profit $-33.0M $-61.0M $-58.0M $-75.0M $-90.0M EPS $-3.20 $-5.50 $-5.07 $-3.96 $0.00 Op Margin -7478.5% -1011633.3% — — —
Balance Sheet (USD)
Metric 2020 2021 2022 2024 2025
Total Assets $211.0M $163.0M $116.0M $336.0M $289.0M Total Liabilities $19.0M $20.0M $22.0M $25.0M $24.0M Cash $193.0M $142.0M $38.0M $137.0M $104.0M Borrowings $12.0M $13.0M $12.0M $12.0M $10.0M
Cash Flow (USD)
Metric 2020 2021 2022 2024 2025
Operating Cash Flow $-25.0M $-48.0M $-46.0M $-71.0M $-77.0M Investing Cash Flow $-4.0M $-7.0M $-60.0M $-126.0M $13.0M Financing Cash Flow $77.0M $1.0M $0 $184.0M $31.0M Net Cash Flow $50.0M $-50.0M $-105.0M $-12.0M $-33.0M Free Cash Flow $-27.0M $-51.0M $-47.0M $-71.0M $-78.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.06 EV / EBITDA 2.69 FCF Yield -1014.70% Quick Ratio 13.08 Interest Coverage -110758.00 Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .